Summary
This Form 8-K/A filing from DexCom, Inc. (DXCM) on January 28, 2009, is an amendment to a previous 8-K filed on November 10, 2008. The primary purpose of this amendment is to formally attach the Collaboration Agreement between DexCom and Edwards Lifesciences LLC as an exhibit. This agreement, originally announced in November 2008, outlines a joint development and marketing effort focused on continuous blood glucose sensing devices specifically for the hospital market. Investors should note that certain portions of the agreement have been redacted and filed separately with the SEC under a confidential treatment request, which is a common practice for sensitive business terms.
Key Highlights
- 1Amendment to a previous 8-K filing concerning a material agreement.
- 2Formal attachment of the Collaboration Agreement with Edwards Lifesciences LLC.
- 3Agreement focuses on joint development and marketing of continuous blood glucose sensing devices.
- 4Target market for the collaboration is the hospital sector.
- 5Certain confidential terms within the agreement have been redacted and filed separately with the SEC.
- 6The filing date for this amendment is January 27, 2009, with the report filed on January 28, 2009.
Frequently Asked Questions
This filing serves as an amendment to a prior 8-K. Its primary purpose is to officially include the full text of the Collaboration Agreement between DexCom and Edwards Lifesciences LLC as an exhibit, which was not attached in the original filing.
DexCom and Edwards Lifesciences are collaborating to jointly develop and market continuous blood glucose sensing devices. The specific application for these devices is within the hospital market.
Certain portions of the agreement have been omitted pursuant to a confidential treatment request. This is a standard practice to protect proprietary business information, such as specific financial terms or strategic details, from public disclosure. These omitted sections have been filed separately with the SEC.
The focus on the hospital market suggests DexCom is looking to expand its reach beyond the current diabetes consumer market into a new, potentially large, institutional setting. This could represent a significant growth opportunity, leveraging the established presence of Edwards Lifesciences in the healthcare industry.